Helix BioPharma Corp. announced the appointment of Dr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out of the Company's lab in Edmonton. Dr. Siegers comes to Helix from IN8bio, where she served as Senior Scientist/Gamma Delta T Cell Specialist.

Prior to this, Dr. Siegers was a Research Associate with the Department of Experimental Oncology at the University of Alberta following postdoctoral studies in Dr. Lynne-Marie Postovits laboratory, where she studied how the tumour microenvironment impacts immune cell function. Prior to this, Dr. Siegers was a Postdoctoral Fellow in the laboratory of Dr. Paula Foster, where she continued research begun in the Translational Cell Therapy Program with Dr. Armand Keating at the Princess Margaret Hospital. Gabrielle M. Siegers (HBSc Guelph, MA Queens) obtained her PhD in Molecular Immunology at the Max Planck Institute for Immunobiology and the University of Freiburg, Germany.

Ms. Siegers returned to Canada to conduct postdoctoral research at the Princess Margaret Hospital, Robarts Research Institute and Western University, and then worked as a Research Associate at the University of Alberta. In 2021, she became an independent scientific consultant and then signed on full time with IN8bio, dividing time between her home office in Edmonton and the lab in Birmingham, Alabama, USA. In August 2022, Ms. Siegers began a new role in Edmonton as Head of R&D for Helix BioPharma.

She has published several original research articles, reviews and book chapters with international and cross-disciplinary collaborators (currently 32 publications on PubMed), and she has given invited talks at national and international meetings in Canada, the United States and Germany.